New cell therapy for MS enters human safety testing

NCT ID NCT07008378

First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 29 times

Summary

This early-stage study tests an experimental treatment called P-CD19CD20-ALLO1 in 60 adults with multiple sclerosis. The main goal is to check if it is safe and how the body handles it. Researchers will also measure how long the treatment lasts in the blood and how it affects immune cells.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Multiple Sclerosis Comprehensive Care Center at Northwell Health

    New York, New York, 10075, United States

  • Rutgers University- Robert Wood Johnson Medical School

    New Brunswick, New Jersey, 08901-1962, United States

  • UCI Sue & Bill Gross Stem Cell Research Center

    Irvine, California, 92697, United States

  • UCSD Altman Clinical and Translational Research Institute

    La Jolla, California, 92037-1337, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110-1010, United States

Conditions

Explore the condition pages connected to this study.